← boardnext 2026-08
ACRS
Aclaris Therapeutics, Inc.distress 4/10 · elevated risk$5.50-2%today-4% from 52w high
Immunology / Inflammation 2
Lead: moderate-to-severe atopic dermatitis · est. market ~$15B (approx, global)
Revenue
pre-revenue
Liquidity
$29M
Runway
0.6 yrs
Shares 1y
+29%
Price & events
+21.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.1%
1D
+2.7%
1W
+11.9%
1M
+21.0%
3M
+22.3%
6M
+227.6%
1Y
+293.1%
2Y
-64.9%
5Y
-15.1%
All
Overview
- Market Cap
- $768.71M
- Volume
- 38.90K
- 52 Week Range
- $1.52 – $5.71
- Total Shares
- 139.66M
- Float Shares
- 113.14M
- Short %
- 9.34%
- % Held by Insiders
- 2.29%
- % Held by Institutions
- 79.63%
- RVOL
- 0.02x
- Beta
- 0.77
Pipeline stages · 1 programs
ATI-045
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 1 upcoming
Catalyst news & presentations · 19
- starting in 2026Guided 40%regulatory submissionFiled (NDA/BLA)next-generation ITK inhibitors · Expected IND submissions for next-generation ITK inhibitorsSEC 8-K
- 2026Guided 40%trial initiationsecondaryPhase 1ITK Selective Inhibitor · IND submission and start of Phase 1 programSEC 8-K
- second half of 2026Guided 55%trial initiationsecondaryPhase 2ATI-2138 · Initiate Phase 2b trialSEC 8-K
- 2H 2026Guided 55%readoutPhase 2bosakitug · Phase 2 top line dataSEC 8-K
- 2H 2026Guided 55%readoutPhase 1ATI-052 · Phase 1b proof-of-concept top line dataSEC 8-K
- second half of 2026Guided 55%trial initiationsecondaryPhase 2Bosakitug (ATI-045) · Initiate Phase 2b trialSEC 8-K
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- second half of 2026readoutPhase 1ATI-052 · Topline data from Phase 1b POC trialsSEC 8-K
- second half of 2026trial initiationsecondaryPhase 2ATI-052 · Initiation of Phase 2b trialSEC 8-K
- early 2026readoutPhase 1ATI-052 · Phase 1a SAD/MAD top line dataSEC 8-K
- first quarter of 2026trial initiationsecondaryPhase 1ATI-052 · Initiation of Phase 1b POC trialSEC 8-K
- October 14, 2025 at 8:00 a.m. ETconferencedata presentationsecondaryIn-person and virtual R&D Day presentation.SEC 8-K
- July 2025readoutPhase 2ATI-2138 · Top line results from Phase 2a open-label trialSEC 8-K
- June 2025readoutPhase 2ATI-2138 · Top line results from Phase 2a trial in moderate-to-severe atopic dermatitisSEC 8-K
- second quarter of 2025trial initiationsecondaryPhase 1ATI-052 · Initiate Phase 1a/1b trial evaluating single and multiple ascending dosesSEC 8-K
- second quarter of 2025trial initiationsecondaryPhase 2bosakitug · Initiate placebo-controlled two-arm Phase 2 trial in moderate-to-severe atopic dermatitisSEC 8-K
- 2025-04-30fda agreementATI-052 · IND cleared by FDA for bispecific anti-TSLP/IL4R antibodySEC 8-K
- 2024-11-18partnershipBSI-502 · Exclusive worldwide license for bispecific antibody BSI-502 (TSLP/IL4R) from Biosion.SEC 8-K
- 2024-07-16partnershipbaricitinib · Aclaris sold portion of future royalties and milestones for OLUMIANT in alopecia areata to OMERS for up to $31.5MSEC 8-K
Approved drugs (1)
- ESKATAHYDROGEN PEROXIDE2017 · Discontinued
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $10 (+82% upside) · 10 analysts
- 2026-06-02LifeSci CapitalOutperform
- 2026-05-05Piper SandlerOverweight
- 2026-05-05GuggenheimBuy
- 2026-04-29WedbushOutperform
- 2026-04-16OppenheimerOutperform
- 2026-03-31WedbushOutperform
Competitors — moderate-to-severe atopic dermatitis
Recent news
- 2026-07-01Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength? - Yahoo Finance
- 2026-06-29Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
- 2026-06-29Aclaris Therapeutics, Inc.(NasdaqGS: ACRS) added to Russell 2500 Growth Benchmark - marketscreener.com
- 2026-06-29Aclaris Therapeutics, Inc.(NasdaqGS: ACRS) added to Russell 3000E Growth Benchmark - marketscreener.com
- 2026-06-28Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell Microcap Growth Benchmark Index - marketscreener.com
- 2026-06-27Price to earnings forward of Aclaris Therapeutics, Inc. – NASDAQ:ACRS - TradingView
- 2026-06-25ACRS Forecast — Price Target — Prediction for 2027 - TradingView
- 2026-06-23We Think Aclaris Therapeutics (NASDAQ:ACRS) Can Afford To Drive Business Growth - Moomoo
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.